Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 0 1 427 0 4 15 2,114
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 0 295 1 2 5 1,325
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 0 8 850
Generic drug pricing in Canada: components of the value-chain 0 0 0 106 0 3 9 337
Microcredit in Pre-Famine Ireland 0 1 3 338 0 4 17 1,787
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 0 6 14 179
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 0 0 8 290
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 0 5 14 258
Subsidizing the Competition 0 0 0 134 1 3 8 690
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 0 324 0 2 9 1,598
Total Working Papers 0 1 4 1,894 2 29 107 9,428


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 0 1 547 1 5 12 4,123
A contractual approach to the gray market 0 0 0 123 0 3 10 417
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 1 1 1 1 1 3 13 17
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 0 1 7 7
Co-authorship and the output of academic economists 0 0 0 72 0 2 11 260
Competition policy in open economies 0 0 0 32 0 1 6 173
Der Green Impact Fund for Technology 0 0 0 3 0 1 9 23
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 0 2 6 24
Governance of electricity transmission systems 0 0 0 81 2 4 12 224
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 0 1 2 192 0 4 11 496
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 0 0 2 0 2 11 25
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 0 37 1 2 10 114
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 0 3 0 3 9 29
Microcredit in Prefamine Ireland 0 0 2 64 1 2 8 276
Microcredit: What can we learn from the past? 0 0 1 328 1 3 10 980
Microfinance and Famine: The Irish Loan Funds during the Great Famine 0 1 1 99 0 5 13 454
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 1 2 34 0 6 19 138
Patient income and health innovation 0 0 0 11 0 3 8 46
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 0 4 8 8
Preliminary Injunctions and Damage Rules in Patent Law 0 0 0 72 2 8 14 345
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 0 4 9 43
Strategic Implications of Learning by Doing 0 0 0 87 0 3 9 570
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 0 15 1 1 10 50
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 0 6 13 743
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 0 4 10 93
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 1 1 1 3 1 2 9 22
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 0 0 0 0 2 4 5
The importance of being first: evidence from Canadian generic pharmaceuticals 0 0 4 310 1 4 21 737
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 1 1 1 61 1 3 18 180
The life-cycle of a microfinance institution: the Irish loan funds 0 0 0 157 0 3 10 467
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 0 0 8 41
Total Journal Articles 3 6 16 2,602 13 96 328 11,130


Statistics updated 2026-06-04